Insights

Why this broker upgraded the embattled Pro Medicus (ASX:PME) share price to “buy”

Could there be some light ahead for the medical software management company?
The post Why this broker upgraded the embattled Pro Medicus (ASX:PME) share price to “buy” appeared first on The Motley Fool Australia. –

Highlights:

Expensive shares like the Pro Medicus share price have crashed in 2022 due to interest rate fears
But Morgans believes the >20% crash in Pro Medicus is a buying opportunity ahead of its results
The broker upgraded its shares to “add” from “hold” with a price target of $54.49 a share

The beaten-down Pro Medicus Limited (ASX: PME) share price could finally be catching a break with Morgans upgrading the company’s shares.

The spectre of rising interest rates has taken its toll on the medical management software company. But the broker believes there is too much bad news priced into the Pro Medicus share price.

This is despite the fact that Pro Medicus is still trading on a FY22 forecast price-to-earnings (P/E) multiple of 100 times.

Why the Pro Medicus share price is tumbling in 2022

Shares trading at a steep premium have taken the brunt of the latest market sell-off. Their valuations take a big haircut as interest rates rise.

The US Federal Reserve is set to lead the way to higher global rates. The central bank is tipped to lift rates three times in 2022, and some experts are warning the Fed could even hike four times to tame inflation.

Against this backdrop, the Pro Medicus share price crashed by around 26% over the past month. It isn’t the only one swept up in ASX market sell-off. The Zip Co Ltd (ASX: Z1P) share price and Megaport Ltd (ASX: MP1) have also shed around 20% each over the period.

Is it time to buy Pro Medicus shares?

But, according to Morgans, investors should consider buying Pro Medicus shares ahead of next month’s profit reporting season. The broker has upgraded its recommendation to “add” from “hold”.

“With the share price now significantly more attractive than it was a month ago, we view current prices as a good entry for long-term investors, but also potential trading positions with reduced risk heading into in the upcoming result,” said the broker.

“Short-term risks around the upcoming results remain with full expectations.

“While we sit slightly below consensus, we view any miss as more likely due to timing of contract recognition rather than overheated underlying expectations.”

Long and shorter-term value emerging

Consensus forecasts have set a high hurdle for management to jump over. The average analyst estimate is for a more than 44% increase in revenue and more than 58% uplift in earnings before interest and tax over the same period last year.

But for those willing to ignore the shorter-term gyrations in earnings and market sentiment, Morgans believes the long-term growth drivers for the Pro Medicus share price remains strong.

Morgan’s 12-month price target on the shares is $54.49. This should give investors around a 20% upside if dividends are included.

The post Why this broker upgraded the embattled Pro Medicus (ASX:PME) share price to “buy” appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

More reading

Are these 2 beaten-up quality ASX shares now buys?

These were the worst performing ASX 200 shares last week

Why Accent, Careteq, Pro Medicus, and Xero shares are dropping

ASX 200 (ASX:XJO) midday update: AGL and Novonix shares shoot higher

What’s going on with the Pro Medicus (ASX:PME) share price?

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended MEGAPORT FPO, Pro Medicus Ltd., and ZIPCOLTD FPO. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended MEGAPORT FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!